Hikma Pharmaceuticals Share News (HIK)

FTSE 100 movers: BP leads market fallers on losses

(ShareCast News) - The FTSE 100 was back below 6,000 on Tuesday, dropping 151.22 points (2.5%) to 5,908.88 by mid-afternoon. BP took the biggest hit after $2.6bn of write-downs and restructuring charges sent it crashing into losses for the fourth quarter and full year. A $3.31bn loss was reported f

BUZZ-Hikma: top of the FTSE 100 on BAML upgrade

** Hikma rises 3 pct after BAML upgrades to "buy" from "neutral" ** Says it sees generous synergies from Roxane Laboratories acquisition; expects co to shut either its own or Roxane's US generics manufacturing plant ** Adds minimal colour on current pipeline but some large opportuniti

BROKER RATINGS SUMMARY: JPMorgan Cuts Merlin To Underweight

BROKER RATINGS SUMMARY: S&P CapIQ Cuts Next To Buy From Strong Buy

Hikma Pharmaceuticals To Sell Ohio-Based Ben Venue Sites To Xellia

LONDON MARKET CLOSE: Stocks End Flat As Investors Await FOMC Minutes

LONDON MARKET MIDDAY: Fed Minutes Awaited For December Rate Hike Clues

WINNERS & LOSERS SUMMARY: Antofagasta, Anglo Up On Goldman Upgrades

LONDON MARKET OPEN: Hikma Shines Amid Downbeat European Markets

LONDON BRIEFING: Hikma And Hunting Gain Amid Weak Early Market

Hikma Says US Regulator Accepts Actions Taken At Portugal Plant

BROKER RATINGS SUMMARY: SocGen Cuts Whitbread To Hold From Buy

Tuesday newspaper share tips: Hikma Pharmaceuticals and Shire under the microscope

(ShareCast News) - Pharmaceuticals were on the newspaper pundits' agenda on Tuesday after Hikma Pharmaceuticals caused a bit of pain. The FTSE 100 company warned on Monday that its generics division is performing below expectations due to slower-than-expected growth in sales for its gout treatment M

BROKER RATINGS SUMMARY: Sells On Barratt, Taylor Wimpey And Persimmon

LONDON MARKET CLOSE: Hikma And Shire Sold Down Amid Firm Market